


APPENDIX

Supplementary Figure 1. Kaplan-Meier curves comparing disease-specific survival (DSS) in clinically node-negative penile squamous cell carcinoma (PSCC) patients who underwent lymph node dissection (LND), stratified by the number of lymph nodes examined.



Supplementary Table 1. Correlation between AJCC T stage and penile cancer treatment modality in T2+N0M0 penile squamous cell carcinoma

Variables	T2	T3	T4	p
All	503	287	35	
Lymph node dissection				0.673
Without	389 (77.3%)	214 (74.6%)	26 (77.1%)	
With	114 (22.7%)	73 (25.4%)	8 (22.9%)	
Chemotherapy				0.009

Fu et al. Survival benefit and utilization disparities of lymph node dissection in clinically node-negative T2+ penile squamous cell carcinoma: A SEER database analysis

Without	491 (97.6%)	274 (95.5%)	31 (88.6%)	
With	12 (2.4%)	13 (4.5%)	4 (11.4%)	
Radiation				0.993
Without	471 (93.6%)	269 (93.7%)	33 (94.3%)	
With	32 (6.4%)	18 (6.3%)	2 (5.7%)	

p<0.05 is considered statistically significant. χ^2 test for categorical variables. AJCC: American Joint Committee on Cancer staging system.

Fu et al. Survival benefit and utilization disparities of lymph node dissection in clinically node-negative T2+ penile squamous cell carcinoma: A SEER database analysis

Supplementary Table 2. Correlation between different race and their diagnosis age of penile cancer.						
	Race					
Age	Hispanic (All Races)	Non-Hispanic American Indian/Alaska Native	Non-Hispanic Asian or Pacific Islander	Non-Hispanic Black	Non-Hispanic White	
25–29 years	2	1	0	0	1	4 (0.5%)
30–34 years	3	0	1	1	3	8 (1.0%)
35–39 years	9	0	0	0	4	13 (1.6%)
40–44 years	13	0	0	5	7	25 (3.0%)
45–49 years	18	0	0	4	13	35 (4.2%)
50–54 years	12	0	4	3	37	56 (6.8%)
55–59 years	24	0	3	4	51	82 (9.9%)
60–64 years	22	1	5	8	49	85 (10.3%)
65–69 years	26	1	5	6	82	120 (14.5%)

Fu et al. Survival benefit and utilization disparities of lymph node dissection in clinically node-negative T2+ penile squamous cell carcinoma: A SEER database analysis

70–74 years	13	1	5	10	76	105 (12.7%)
75–79 years	16	0	2	6	85	109 (13.2%)
80–84 years	10	0	4	6	63	83 (10.1%)
85+ years	15	1	5	11	68	100 (12.1%)
	183 (22.2%)	5 (0.6%)	34 (4.1%)	64 (7.8%)	539 (65.3%)	825
						<0.001